Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report)'s share price fell 5.2% during trading on Thursday . The stock traded as low as $11.90 and last traded at $11.97. 42,924 shares were traded during trading, a decline of 88% from the average session volume of 347,709 shares. The stock had previously closed at $12.63.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "buy" rating and set a $38.00 price target on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Pliant Therapeutics currently has a consensus rating of "Buy" and an average target price of $40.50.
Read Our Latest Report on Pliant Therapeutics
Pliant Therapeutics Trading Down 3.4 %
The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $682.13 million, a price-to-earnings ratio of -3.36 and a beta of 1.05. The firm's 50 day moving average is $13.43 and its 200 day moving average is $13.03.
Hedge Funds Weigh In On Pliant Therapeutics
A number of hedge funds have recently modified their holdings of PLRX. Atria Investments Inc acquired a new position in shares of Pliant Therapeutics in the 3rd quarter valued at $112,000. Deerfield Management Company L.P. Series C purchased a new position in shares of Pliant Therapeutics in the second quarter worth approximately $126,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Pliant Therapeutics by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company's stock valued at $131,000 after acquiring an additional 4,607 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Pliant Therapeutics in the 3rd quarter valued at approximately $145,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Pliant Therapeutics in the 3rd quarter worth approximately $342,000. 97.30% of the stock is currently owned by institutional investors and hedge funds.
Pliant Therapeutics Company Profile
(
Get Free Report)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
See Also
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
